Loading clinical trials...

Using Text Messages to Boost COVID-19 Vaccine Booking Rate | Clinical Trials | Clareo Health

COMPLETEDNA

Using Text Messages to Boost COVID-19 Vaccine Booking Rate

Using Text Messages to Boost COVID-19 Vaccination Appointment Booking and Vaccination Rates: A Randomised Controlled Field Trial.

NCT05993260•The Behavioural Insights Team

View on ClinicalTrials.gov

Summary

This study is a nationwide randomised controlled trial (RCT) to test the impact of behavioural science-informed text messages notifying patients of their eligibility for the COVID-19 vaccine on vaccination rates.

Eligibility

Age

40 - 44 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•(i) satisfying the age criteria as defined above;
•(ii) recorded in the National Immunisation Management System (NIMS);
•(iii) with a valid mobile phone number;
•(iv) who had not already received or been invited for the COVID-19 vaccine via NIMS at the time of the study.

Exclusion Criteria

•Participants with invalid phone numbers

Locations (1)

NHS England

London, United Kingdom

Key Dates

Start Date

April 26, 2021

Primary Completion Date

April 29, 2021

Completion Date

May 10, 2021

Last Updated

August 15, 2023

Enrollment

1,825,937

ACTUAL participants

Conditions

Vaccination HesitancyCOVID-19

Interventions

Behavioural science-informed text messages

BEHAVIORAL

Control

BEHAVIORAL

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITINGPHASE1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 15, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Using Text Messages to Boost COVID-19 Vaccine Booking Rate

Inclusion Criteria

Exclusion Criteria

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate

Positron Emission Tomography (PET) Imaging of Thrombosis